What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?

In the absence of a clinical trial option for this patient with triple-negative breast cancer (TNBC) who had completed the KEYNOTE-522 regimen <12 months ago for non-metastatic TNBC and who now has metastatic TNBC which tested PD-L1 positive (PD-L1 CPS >10), I would offer immunotherapy with pembroli...